ReviewNature reviews. Nephrology2016
Memory T cells in organ transplantation: progress and challenges.
Review in Nature reviews. Nephrology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 64 citations in OpenAlex.
- Challenges of calcineurin inhibitor withdrawal following combined pancreas and kidney transplantation: Results of a prospective, randomized clinical trial.American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2020Trial
- Endothelial MHC expression is required to initiate T cell-mediated rejection of 3D-printed skin grafts.JCI insight · 2026Article
- BHLHE40 Orchestrates Effector Tissue-Resident Memory CD8Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- The dual role of T cells in solid organ transplant rejection and immune tolerance.Frontiers in immunology · 2026Review
- Providing care for kidney transplant recipients: An overview for generalists.World journal of nephrology · 2025Review
- Cytotoxic KLRG1+ IL-7R- effector CD8+ T cells distinguish kidney transplant recipients controlling cytomegalovirus reactivation.Frontiers in immunology · 2025Article
- Mechanisms of allorecognition and xenorecognition in transplantation.Clinical transplantation and research · 2024Review
- The immune regulatory role of lymphangiogenesis in kidney disease.Journal of translational medicine · 2024Review
- Pregnancy dedifferentiates memory CD8+ T cells into hypofunctional cells with exhaustion-enriched programs.JCI insight · 2024Article
- T-cell receptor sequencing reveals selected donor-reactive CD8American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2024Article
- Immunoprotection of cellular transplants for autoimmune type 1 diabetes through local drug delivery.Advanced drug delivery reviews · 2024Review
- Alloreactive T cells to Assess Acute Rejection Risk in Kidney Transplant Recipients.Transplantation direct · 2023Article
- mTOR Inhibition Impairs the Activation and Function of Belatacept-Resistant CD4Pharmaceutics · 2023Article
- Comparative effects of hepatocyte growth factor and tacrolimus on acute liver allograft early tolerance.Frontiers in immunology · 2023Article
- Preservation of Antiviral Immunologic Efficacy Without Alloimmunity After Switch to Belatacept in Calcineurin Inhibitor-Intolerant Patients.Kidney international reports · 2023Article
- Article
- Blocking hyaluronan synthesis alleviates acute lung allograft rejection.JCI insight · 2021Article
- Designing biomaterials for the modulation of allogeneic and autoimmune responses to cellular implants in Type 1 Diabetes.Acta biomaterialia · 2021Review
- The lymphatics in kidney health and disease.Nature reviews. Nephrology · 2021Review
- Innate allorecognition in transplantation.The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
Antigen-experienced T cells, also known as memory T cells, are functionally and phenotypically distinct from naive T cells. Their enhanced expression of adhesion molecules and reduced requirement for co-stimulation enables them to mount potent and rapid recall responses to subsequent antigen encounters. Memory T cells generated in response to prior antigen exposures can cross-react with other nonidentical, but similar, antigens. This heterologous cross-reactivity not only enhances protective immune responses, but also engenders de novo alloimmunity. This latter characteristic is increasingly recognized as a potential barrier to allograft acceptance that is worthy of immunotherapeutic intervention, and several approaches have been investigated. Calcineurin inhibition effectively controls memory T-cell responses to allografts, but this benefit comes at the expense of increased infectious morbidity. Lymphocyte depletion eliminates allospecific T cells but spares memory T cells to some extent, such that patients do not completely lose protective immunity. Co-stimulation blockade is associated with reduced adverse-effect profiles and improved graft function relative to calcineurin inhibition, but lacks efficacy in controlling memory T-cell responses. Targeting the adhesion molecules that are upregulated on memory T cells might offer additional means to control co-stimulation-blockade-resistant memory T-cell responses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.